Advertisement

Dose-Dependent Pharmacokinetics of Clofibric Acid in the Non-human Primate

  • L. M. Walmsley
Conference paper
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 7)

Abstract

The pharmacokinetics of clofibric acid (CPIB, the active metabolite of Clofibrate) has been studied in two species of non-human primate after administration by two routes at three dose levels. Plasma CPIB concentrations were determined by HPLC. In both the cynomolgus monkey and the baboon, the systemic availability of orally administered CPIB did not differ significantly from 100%; the rates of bioavailability, however, showed a dose-related trend. At the lowest dose level (15 mg/kg), the plasma concentration-time profile appeared to follow first order kinetics, with an apparent t ½ of 1 h; at dose levels which might be used in toxicity studies (45 and 150 mg/kg) the apparent t ½ was longer, indicating dose-related trends by both routes of administration. The pharmacokinetics of CPIB are therefore non-linear over the dose range considered.

CPIB protein binding was concentration-dependent over the range 50–700 μg/ml. Re-estimation of kinetic parameters in terms of free drug concentration did not remove the non-linearity. It is concluded that the pharmacokinetics of CPIB in the non-human primate are dose-dependent but that the extent of absorption of an oral dose was independent of dose level over the range studied.

Key words

Clofibric acid 2-(4-chlorophenoxy)-2-methylpropanoic acid (CPIB) Clofibrate Clofibride Bioavailability Half-life (t½Kinetics Plasma Primate Protein binding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cayen MN (1983) Metabolism and pharmacokinetics of antihyperlipidaemic agents. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 7. Wiley, London, pp 173–227Google Scholar
  2. Gugler R, Hartlapp J (1978) Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther 24: 432–438PubMedGoogle Scholar
  3. Loiseau GP, Miliischer RJ, Lohier PY, Mardiguian JS, Gilede AP, Ginocchio AV (1980) On the metabolism of clofibride, a hypolipaemic drug. J Pharm Pharmacol 32: 483–488PubMedCrossRefGoogle Scholar
  4. Thorp JM (1962) Experimental evaluation of an orally active combination of aldosterone with ethyl chlorophenoxyisobutyrate. Lancet 1: 1323–1326CrossRefGoogle Scholar
  5. Wagner JG (1975) Fundamentals of clinical pharmacokinetics, 1st edn. Drug Intelligence, Hamilton, Ill., pp 247–283Google Scholar
  6. Waller AR, Chasseaud LF, Taylor T (1984) Bioavailability studies of etofibrate in rhesus monkeys (in press)Google Scholar
  7. Woodhouse RN, Cresswell DG, Chasseaud LF, Brodie RR (1977) Use of high performance liquid chromatography to measure plasma concentrations of p-chlorophenoxyisobutyric acid after administration of Clofibrate to humans. J Chromatogr 137: 218–221PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • L. M. Walmsley
    • 1
  1. 1.Huntingdon Research CentreHuntingdon, CambsGreat Britain

Personalised recommendations